{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["7(4)"],"submitter":["Heynen GJJE"],"pubmed_abstract":["Proteasome inhibition is a highly effective treatment for multiple myeloma (MM). However, virtually all patients develop proteasome inhibitor resistance, which is associated with a poor prognosis. Hyperactive small ubiquitin-like modifier (SUMO) signaling is involved in both cancer pathogenesis and cancer progression. A state of increased SUMOylation has been associated with aggressive cancer biology. We found that relapsed/refractory MM is characterized by a SUMO-high state, and high expression of the SUMO E1-activating enzyme (SAE1/UBA2) is associated with poor overall survival. Consistently, continuous treatment of MM cell lines with carfilzomib (CFZ) enhanced SUMO pathway activity. Treatment of MM cell lines with the SUMO E1-activating enzyme inhibitor subasumstat (TAK-981) showed syne"],"journal":["Blood advances"],"pagination":["469-481"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9979771"],"repository":["biostudies-literature"],"pubmed_title":["SUMOylation inhibition overcomes proteasome inhibitor resistance in multiple myeloma."],"pmcid":["PMC9979771"],"pubmed_authors":["Janz M","Kronke J","Nogai A","Wirth M","Muller S","Holz M","Murgai A","Heider M","Heynen GJJE","Kaiser M","Ng YLD","Demel UM","Bamopoulos SA","Keller U","Schaffer I","Ramberger E","Kruger J","Bassermann F","Laue D","Patra U","Braune J","Mertins P","Liebig S","Baumgartner F","Schick M"],"additional_accession":[]},"is_claimable":false,"name":"SUMOylation inhibition overcomes proteasome inhibitor resistance in multiple myeloma.","description":"Proteasome inhibition is a highly effective treatment for multiple myeloma (MM). However, virtually all patients develop proteasome inhibitor resistance, which is associated with a poor prognosis. Hyperactive small ubiquitin-like modifier (SUMO) signaling is involved in both cancer pathogenesis and cancer progression. A state of increased SUMOylation has been associated with aggressive cancer biology. We found that relapsed/refractory MM is characterized by a SUMO-high state, and high expression of the SUMO E1-activating enzyme (SAE1/UBA2) is associated with poor overall survival. Consistently, continuous treatment of MM cell lines with carfilzomib (CFZ) enhanced SUMO pathway activity. Treatment of MM cell lines with the SUMO E1-activating enzyme inhibitor subasumstat (TAK-981) showed syne","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Feb","modification":"2026-05-28T18:37:34.498Z","creation":"2025-02-19T04:55:03.923Z"},"accession":"S-EPMC9979771","cross_references":{"pubmed":["35917568"],"doi":["10.1182/bloodadvances.2022007875"]}}